You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

Drug Price Trends for LO-ZUMANDIMINE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for LO-ZUMANDIMINE

Average Pharmacy Cost for LO-ZUMANDIMINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
LO-ZUMANDIMINE 3 MG-0.02 MG TB 59651-0029-28 0.14233 EACH 2025-01-22
LO-ZUMANDIMINE 3 MG-0.02 MG TB 59651-0029-88 0.14233 EACH 2025-01-22
LO-ZUMANDIMINE 3 MG-0.02 MG TB 59651-0029-28 0.15099 EACH 2024-12-18
LO-ZUMANDIMINE 3 MG-0.02 MG TB 59651-0029-88 0.15099 EACH 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Lo-Zumandimine

Introduction to Lo-Zumandimine

Lo-Zumandimine is a combination oral contraceptive (COC) that contains drospirenone, a progestin, and ethinyl estradiol, an estrogen. It is indicated for use by females of reproductive potential to prevent pregnancy, treat symptoms of premenstrual dysphoric disorder (PMDD), and treat moderate acne[1].

Market Demand and Indications

Lo-Zumandimine is part of a broader market for oral contraceptives, which includes various brand names such as Yaz, Yasmin, Ocella, and Loryna. The demand for these products is driven by the need for effective contraception, as well as the additional benefits of treating PMDD and acne.

  • Contraception: The primary indication for Lo-Zumandimine is to prevent pregnancy, making it a staple in the reproductive health market.
  • PMDD: Lo-Zumandimine is also indicated for the treatment of PMDD symptoms, which expands its market to include women seeking relief from severe premenstrual symptoms.
  • Acne: The treatment of moderate acne in women at least 14 years old further broadens its market appeal[1].

Competitive Landscape

The market for COCs is highly competitive, with several brands and generic versions available. Lo-Zumandimine competes with other drospirenone and ethinyl estradiol combinations such as Yaz, Yasmin, and Ocella. The presence of generic versions of these drugs also impacts the pricing and market share of branded products[4].

Pricing and Cost Analysis

The pricing of Lo-Zumandimine can vary based on several factors, including the pharmacy, location, and availability of discounts or patient assistance programs.

  • Cash Prices: For cash-paying customers, the cost of Lo-Zumandimine can range from approximately $28.27 for a 28-tablet supply to $65.80 for an 84-tablet supply[2][4].
  • Discounts and Coupons: The use of discount cards, such as those offered by Drugs.com, can significantly reduce the cost, potentially saving up to 80% off the retail price[2].
  • Patient Assistance Programs: Programs like the Patient Access Network Foundation (PAN) offer cost-free or discounted medicines to eligible individuals, further reducing the financial burden for some patients[2].

Price Projections

Given the competitive nature of the market and the availability of generic versions, price projections for Lo-Zumandimine are likely to remain stable or see a slight decrease.

  • Generic Competition: The presence of generic drospirenone and ethinyl estradiol tablets will continue to pressure the pricing of branded products like Lo-Zumandimine.
  • Market Dynamics: As more patients opt for generic versions due to cost considerations, the market share of branded products may decrease, leading to potential price adjustments to remain competitive.
  • Economic Factors: Economic conditions, such as inflation and changes in healthcare policies, can also influence pricing. However, given the essential nature of contraceptive medications, significant price hikes are unlikely.

Consumer Behavior and Preferences

Consumer behavior plays a crucial role in the market for Lo-Zumandimine. Key factors include:

  • Brand Loyalty: Some consumers may prefer branded products like Lo-Zumandimine due to perceived quality and effectiveness, despite the availability of generics.
  • Cost Sensitivity: Many consumers are highly cost-sensitive and will opt for the most affordable option, which could be a generic version.
  • Healthcare Provider Influence: Recommendations from healthcare providers can significantly influence consumer choice, with some providers preferring certain brands over others based on patient needs and safety profiles[1].

Safety and Risk Considerations

The safety profile of Lo-Zumandimine, particularly its association with an increased risk of venous thromboembolism (VTE), is a critical factor in market analysis. This risk, although lower than that during pregnancy and the postpartum period, must be carefully considered by healthcare providers and patients[3][5].

Regulatory Environment

Regulatory changes and safety updates can impact the market for Lo-Zumandimine. For instance, the FDA's safety statements and boxed warnings regarding the risk of thromboembolism can influence prescribing practices and consumer confidence[3].

Key Takeaways

  • Market Demand: Lo-Zumandimine benefits from a strong demand driven by its multiple indications.
  • Pricing: Prices are competitive, with discounts and patient assistance programs available to reduce costs.
  • Generic Competition: The presence of generic versions pressures the pricing of branded products.
  • Safety Profile: The risk of VTE is a significant consideration that affects market dynamics.
  • Regulatory Environment: Regulatory updates and safety statements can impact market trends.

FAQs

1. What are the primary indications for Lo-Zumandimine? Lo-Zumandimine is indicated for preventing pregnancy, treating symptoms of premenstrual dysphoric disorder (PMDD), and treating moderate acne in women at least 14 years old[1].

2. How does the pricing of Lo-Zumandimine compare to its generic versions? The pricing of Lo-Zumandimine can range from $28.27 to $65.80 for different supply quantities, while generic versions can be significantly cheaper, starting from around $28.27 for a 28-tablet supply[2][4].

3. What are the key safety considerations for Lo-Zumandimine? Lo-Zumandimine is associated with an increased risk of venous thromboembolism (VTE), and it is contraindicated in patients with certain conditions such as renal impairment, adrenal insufficiency, and liver disease[1][3].

4. Are there any patient assistance programs available for Lo-Zumandimine? Yes, programs like the Patient Access Network Foundation (PAN) offer cost-free or discounted medicines to eligible individuals[2].

5. How does the regulatory environment impact the market for Lo-Zumandimine? Regulatory updates and safety statements from the FDA can influence prescribing practices and consumer confidence, thereby impacting market trends[3].

Cited Sources

  1. Drugs.com: Lo-Zumandimine: Package Insert / Prescribing Information[1].
  2. Drugs.com: Lo-Zumandimine Prices, Coupons, Copay Cards & Patient Assistance[2].
  3. DrugBank: Drospirenone: Uses, Interactions, Mechanism of Action[3].
  4. Drugs.com: Drospirenone/ethinyl estradiol Prices, Coupons, Copay Cards & Patient Assistance[4].
  5. PDR.net: Yaz - Drug Summary[5].

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.